Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of $6.51M (cash outflow) fell 20.6% year over year, ahead of the -50.5% change in trailing-twelve-month free cash flow. Over 3 fiscal years it compounded at -26.9% a year.

Context

  • Free cash flow amounted to 1151.4% of revenue in FY2025, down 2327.6 pp from a year earlier.
  • Free cash flow grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -20.6% holds above the trailing-twelve-month pace of -50.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.51M-2315.0% QoQ
Last fiscal yearDec 2025
-$18.8M-47.4% YoY
LTMMar 2026
-$17.11M-50.5% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.6%——
1 year-47.4%——
3-year CAGR-26.9%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(18.8M) USD
Year-over-year change
+47.4%

Free Cash Flow vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -50.5% is the lowest of 9, against a peer median of +48.8%.
  • Free cash flow amounts to 540.0% of revenue for RANI, versus a peer median of 1823.0%.
RANI Competitors
Free Cash Flow for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$132.65M USD+121.3%-11.0%755.6%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$90.46M USD+101.5%-26.4%261.8%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$73.65M USD+46.6%+19.8%—
MOLNMolecular Partners AGLTM Mar 2026CHF 54.13M CHF-8.4%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$51.23M USD+51.1%-2.2%2871.8%
IPHAInnate Pharma S.A.FY2025€50.81M EUR+597.2%+35.8%1823.0%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$38.49M USD+9.5%+17.4%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$37.46M USD-12.4%+3.0%7135.4%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$17.11M USD-50.5%-26.9%540.0%
Peer median (excluding RANI) —+48.8%+3.0%1823.0%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.33M)(63.34M)(33.97M)(56.58M)(29.67M)
Depreciation & Amortization497K548K822K1.03M900K
Deferred Income Tax00000
Stock-Based Compensation22.6M15.78M19.01M16.03M11.8M
Change in Working Capital(3.43M)509K(2.14M)(544K)6.96M
Accounts Receivables000(428K)(1.61M)
Inventory00000
Accounts Payables543K163K(595K)711K(1.05M)
Other Working Capital(3.97M)346K(1.55M)(827K)9.62M
Other Non-Cash Items(43.58M)(10K)(34.96M)4.57M(8.7M)
Operating Cash Flow(32.25M)(46.52M)(51.24M)(35.5M)(18.71M)
Capital Expenditures(506K)(1.62M)(1.23M)(268K)(88K)
Acquisitions (Net)0(851K)000
Purchases of Investments0(73.82M)(73.26M)(58.72M)(33.97M)
Sales of Investments03M104.35M77.55M26.75M
Other Investing Activities0851K01.25M278K
Investing Cash Flow(506K)(72.44M)29.86M19.81M(7.03M)
Debt Repayment(2.85M)29.57M0(5M)(20.72M)
Common Stock Issued73.65M317K395K18.63M61.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities26K(886K)(162K)(47K)(59K)
Financing Cash Flow77.15M29.01M233K13.59M40.3M
Effect of Forex Changes00000
Net Change in Cash44.4M(89.95M)(21.14M)(2.1M)14.56M
Free Cash Flow(32.75M)(48.13M)(52.47M)(35.76M)(18.8M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.